CompletedPhase 4
EMPagliflozin after Aortic Valve Replacement - the EMPAVR study
Key facts
- Who runs it
- Rigshospitalet
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 206 people enrolled
- Started
- 7 Feb 2024
- Ended
- 8 May 2026
- Type of study
- Interventional
- Record updated
- 22 July 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Severe symptomatic AS AND Surgical or transcatheter AVR within 14 days
Who cannot take part
- Prior treatment with an SGLT2i
- Hypersensitivity to empagliflozin or placebo tablet
- LVEF <45%
- eGFR <30ml/min
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this trial is to test whether SGLT2 inhibition after AVR is superior to placebo in reducing left ventricular mass and improve patient symptoms.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- EMPagliflozin after Aortic Valve Replacement - the EMPAVR study - a randomized clinical trial
- Record updated
- 22 July 2024